Identification of the atypical antipsychotic Asenapine as a direct survivin inhibitor with anticancer properties and sensitizing effects to conventional therapies
Authors:
- Cristina Benítez-GarcíaCBCristina Benítez-García
- David Martínez-GarcíaDMDavid Martínez-García
- Martin KotevMKMartin Kotev
- Marta Pérez-HernándezMPMarta Pérez-Hernández
- Yvonne WestermaierYWYvonne Westermaier
- Lucía DíazLDLucía Díaz
- Pere FontovaPFPere Fontova
- Ana Aurora TorresATAna Aurora Torres
- María García-ValverdeMGMaría García-Valverde
- Roberto QuesadaRoberto Quesada
Open Access
- 17 December 2024
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 182, 117756
Abstract
No abstract availableKeywords
Funding Information
- Ministerio de Ciencia e Innovación
- Horizon 2020 Framework Programme (PTQ-PTQ-16-08333)
- Horizon 2020 (BioExcel-3 101093290)
- European Regional Development Fund (BU067P20)
- Consejería de Educación, Junta de Castilla y León
- Instituto de Salud Carlos III (PI22/00256)
- Instituto de Salud Carlos III (PI18/00441)
This publication has 50 references indexed in Scilit:
- XIAP as a multifaceted molecule in Cellular SignalingApoptosis, 2022
- Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancerCancer Chemotherapy and Pharmacology, 2020
- Therapeutic strategies involving survivin inhibition in cancerMedicinal Research Reviews, 2018
- Sensitization of colorectal cancer cells to irinotecan by the Survivin inhibitor LLP3 depends on XAF1 proficiency in the context of mutated p53Archives of Toxicology, 2018
- Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)Apoptosis, 2017
- A phase 2, multicenter, open‐label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanomaCancer Medicine, 2014
- Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)Investigational New Drugs, 2013
- Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cellsInvestigational New Drugs, 2013
- Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancerJournal of Surgical Oncology, 2011
- Survivin: a promising biomarker for detection and prognosis of bladder cancerWorld Journal of Urology, 2007